Evidence map›Paper›PMID 41480597›Full record

ArticleWorld journal of diabetes2025

Glycemic control, weight-loss effects, and safety of cotadutide in individuals with type 2 diabetes: A systematic review and meta-analysis.

Abul Bashar Mohammad Kamrul-Hasan, Deep Dutta, Lakshmi Nagendra, Sindhu Doddabokikere Basavarajappa, Harish Bukkasagar Girijashankar, Ameya Joshi, Joseph M Pappachan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of diabetes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Abul Bashar Mohammad Kamrul-HasanDepartment of Endocrinology, Mymensingh Medical College, Mymensingh 2200, Bangladesh.
Deep DuttaDepartment of Endocrinology, CEDAR Superspeciality Healthcare, New Delhi 110075, Delhi, India.
Lakshmi NagendraDepartment of Endocrinology, JSS Medical College, JSS Academy of Higher Education and Research, Mysuru 570015, Karnataka, India.
Sindhu Doddabokikere BasavarajappaDepartment of Medical Statistics, School of Life Sciences, JSS Academy of Higher Education and Research, Mysuru 570015, Karnataka, India.
Harish Bukkasagar GirijashankarDepartment of Anesthesiology, JSS Medical College, JSS Academy of Higher Education and Research, Mysuru 570015, Karnataka, India.
Ameya JoshiDepartment of Endocrinology, Bhaktivedanta Hospital & Research Institute, Thane 401107, Maharashtra, India.
Joseph M PappachanFaculty of Science, Manchester Metropolitan University, Manchester M15 6BH, Greater Manchester, United Kingdom.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCotadutide (MEDI0382) is a twincretin that acts as an agonist for both the glucagon-like peptide-1 and glucagon receptors. Several randomized controlled trials (RCTs) have been published evaluating the use of cotadutide in individuals with type 2 diabetes (T2D), showing promising results. However, the efficacy and safety of the drug use have been inadequately explored by systematic reviews and meta-analyses.

aimTo assess the clinical efficacy and safety of cotadutide in individuals with T2D having overweight or obesity.

methodsThe systematic reviews and meta-analyses have been registered with International Prospective Register of Systematic Reviews (CRD42024511703), and the protocol summary can be accessed online. Several databases and registries, including MEDLINE (

resultsNine RCTs (mostly phase 2 RCTs,

conclusionCotadutide demonstrated glycemic control and weight-loss benefits in short-term, small RCTs (mostly phase 2). However, small sample sizes, very low to low certainty of evidence, and the absence of data on long-term cardiovascular and renal outcomes highlight substantial uncertainties, warranting cautious interpretation and further investigation in larger, longer-term trials to establish its safety and efficacy profile.

Indexed as

Adverse eventsBody weightCotadutideDiabesityGlycated hemoglobinObesityType 2 diabetes

Identifiers

PMID41480597
PMCPMC12754120

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.